NorthView Acquisition Corp. Files Q2 2024 10-Q Report

TL;DR

NorthView Acquisition Corp. filed its 10-Q for Q2 2024. Check financials.

AI Summary

NorthView Acquisition Corp. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Delaware, is involved in the Surgical & Medical Instruments & Apparatus industry. Its principal executive offices are located at 207 West 25th St, 9th Floor, New York, NY 10001.

Why It Matters

This filing provides investors with an update on NorthView Acquisition Corp.'s financial performance and operational status for the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a standard 10-Q filing for a publicly traded company, providing routine financial disclosures.

Key Numbers

• 001-41177 — SEC File Number (Identifies the company's filing with the SEC.)
• 86-3437271 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• NorthView Acquisition Corp. (company) — Registrant
• June 30, 2024 (date) — Quarterly period end date
• 207 West 25th St, 9th Floor, New York, NY 10001 (address) — Principal executive offices
• Delaware (jurisdiction) — State of incorporation
• Surgical & Medical Instruments & Apparatus [3841] (industry) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NVAC The Nasdaq Sto
• $11.50 — of common stock at an exercise price of $11.50 per whole share NVACW The Nasdaq Stock
• $11.13 — k were redeemed at a per share price of $11.13. In January 2024, $1,565,078 was paid f
• $1,565,078 — share price of $11.13. In January 2024, $1,565,078 was paid from the Trust Account to rede

Filing Documents

• ea0220952-10q_northview.htm (10-Q) — 645KB
• ea022095201ex31-1_northview.htm (EX-31.1) — 12KB
• ea022095201ex31-2_northview.htm (EX-31.2) — 12KB
• ea022095201ex32-1_northview.htm (EX-32.1) — 5KB
• ea022095201ex32-2_northview.htm (EX-32.2) — 5KB
• 0001213900-24-098671.txt ( ) — 4737KB
• nvac-20240630.xsd (EX-101.SCH) — 43KB
• nvac-20240630_cal.xml (EX-101.CAL) — 22KB
• nvac-20240630_def.xml (EX-101.DEF) — 256KB
• nvac-20240630_lab.xml (EX-101.LAB) — 374KB
• nvac-20240630_pre.xml (EX-101.PRE) — 252KB
• ea0220952-10q_northview_htm.xml (XML) — 534KB

Financial Information

Part I. Financial Information 1 Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 1 Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended June 30, 2024 and 2023 3 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures Regarding Market Risk

Quantitative and Qualitative Disclosures Regarding Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

Other Information

Part II. Other Information 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

Signatures

Part III. Signatures 31 i

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. NORTHVIEW ACQUISITION CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2024 (Unaudited) December 31, 2023 Assets Current Assets: Cash $ 6,496 $ 4,519 Prepaid expenses and other current assets 40,500 6,750 Prepaid income taxes 66,525 — Cash and marketable securities held in Trust Account — 1,565,078 Total Current Assets 113,521 1,576,347 Cash and marketable securities held in Trust Account 8,476,424 9,308,328 Total Assets $ 8,589,945 $ 10,884,675 Liabilities, Redeemable Common Stock and Stockholders' Deficit Current Liabilities: Accounts payable and accrued expenses $ 704,831 $ 449,114 Excise tax payable 1,874,990 1,864,106 Common stock to be redeemed (1) — 1,565,078 Income tax payable — 49,061 Convertible promissory note 1,527,001 944,118 Due to related party 50,000 50,000 Total Current Liabilities 4,156,822 4,921,477 Deferred tax liability — 13,661 Warrant liabilities 957,234 156,639 Total Liabilities 5,114,056 5,091,777 Commitments and Contingencies (Note 6) Common stock subject to possible redemption, 738,075 and 833,469 shares at redemption value of approximately $ 11.59 and $ 11.10 at June 30, 2024 and December 31, 2023, respectively 8,550,909 9,252,208 Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 1,000,000 shares authorized; none issued and outstanding — — Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 5,193,750 shares issued and outstanding at June 30, 2024 and December 31, 2023 (excluding 738,075 and 833,469 shares subject to possible redemption at June 30, 2024 and December 31, 2023, respectively) 519 519 Accumulated deficit ( 5,075,539 ) ( 3,459,829 ) Total Stockholders' Deficit ( 5,075,020 ) ( 3,459,310 ) Total Liabilities, Redeemable Common Stock and Stockholders' Deficit $ 8,589,945 $ 10,884,675 (1) In connection with the special meeting of stockholders to vote on extendin

View Full Filing

View this 10-Q filing on SEC EDGAR